Momenta Pharmaceuticals Stock Price, News & Analysis (NASDAQ:MNTA)

$16.40 1.25 (8.25 %)
(As of 01/22/2018 01:15 PM ET)
Previous Close$15.15
Today's Range$14.89 - $17.35
52-Week Range$11.85 - $19.90
Volume2.34 million shs
Average Volume1.20 million shs
Market Capitalization$1.23 billion
P/E Ratio-20.50
Dividend YieldN/A
Beta1.66

About Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals logoMomenta Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on developing generic versions of drugs, biosimilars and therapeutics for oncology and autoimmune disease. The Company has developed generic version of LOVENOX (enoxaparin sodium injection) and COPAXONE (glatiramer acetate injection). GLATOPA 20 milligrams (mg)/ milliliters (mL) is a generic version of once-daily COPAXONE 20 mg/mL indicated for the treatment of patients with relapsing forms of multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. COPAXONE is available in both a once-daily 20 mg/mL formulation and a three-times-weekly 40 mg/mL formulation. The Company's Enoxaparin Sodium Injection is a generic version of LOVENOX indicated for the prevention and treatment of deep vein thrombosis and to support the treatment of acute coronary syndromes. The Company's programs include M254, M281 (Anti-FcRn candidate) and M230.

Receive MNTA News and Ratings via Email

Sign-up to receive the latest news and ratings for MNTA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorBiotechnology & Medical Research - NEC
SymbolNASDAQ:MNTA
CUSIP60877T10
Phone+1-617-4919700

Debt

Debt-to-Equity RatioN/A
Current Ratio4.16%
Quick Ratio4.16%

Price-To-Earnings

Trailing P/E Ratio-20.5
Forward P/E Ratio-14.14
P/E GrowthN/A

Sales & Book Value

Annual Sales$109.62 million
Price / Sales11.43
Cash FlowN/A
Price / CashN/A
Book Value$5.22 per share
Price / Book3.14

Profitability

Trailing EPS($0.80)
Net Income$-21,000,000.00
Net Margins-55.61%
Return on Equity-16.20%
Return on Assets-11.82%

Miscellaneous

Employees290
Outstanding Shares76,390,000

Momenta Pharmaceuticals (NASDAQ:MNTA) Frequently Asked Questions

What is Momenta Pharmaceuticals' stock symbol?

Momenta Pharmaceuticals trades on the NASDAQ under the ticker symbol "MNTA."

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) issued its earnings results on Wednesday, November, 1st. The biotechnology company reported ($0.44) earnings per share for the quarter, topping the Thomson Reuters' consensus estimate of ($0.47) by $0.03. The biotechnology company had revenue of $24.09 million for the quarter, compared to analyst estimates of $29.58 million. Momenta Pharmaceuticals had a negative return on equity of 16.20% and a negative net margin of 55.61%. The firm's revenue for the quarter was down 17.3% on a year-over-year basis. During the same period last year, the company earned ($0.26) earnings per share. View Momenta Pharmaceuticals' Earnings History.

When will Momenta Pharmaceuticals make its next earnings announcement?

Momenta Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, February, 19th 2018. View Earnings Estimates for Momenta Pharmaceuticals.

Where is Momenta Pharmaceuticals' stock going? Where will Momenta Pharmaceuticals' stock price be in 2018?

9 brokerages have issued 12-month price objectives for Momenta Pharmaceuticals' shares. Their predictions range from $6.00 to $18.00. On average, they expect Momenta Pharmaceuticals' share price to reach $14.44 in the next twelve months. View Analyst Ratings for Momenta Pharmaceuticals.

What are Wall Street analysts saying about Momenta Pharmaceuticals stock?

Here are some recent quotes from research analysts about Momenta Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Momenta’s third-quarter results were overshadowed by the disappointing results from a phase I study on the proposed biosimilar verison of Orencia. Momenta announced that M834 did not meet its primary pharmacokinetic end points in a phase I study to compare the pharmacokinetics, safety and immunogenicity of M834 to Orencia in normal healthy volunteers. Earlier, Momenta suffered a blow when the FDA approved Mylan’s generic version of Copaxone 40 mg. On the other hand, Momenta’s ANDA approval for Glatopa is contingent on the satisfactory resolution of the compliance observations stated in the warning letter issued by the FDA, resulting in a delay of approval. The warning letter will remain a major over hang on the shares till the issue is solved. Moreover, shares of the company have underperformed the industry in the last six months." (1/2/2018)
  • 2. Cowen Inc analysts commented, "Glatopa sales were $23M primarily, above our estimate of $20M driven by quarterly." (5/3/2017)
  • 3. Aegis analysts commented, "Warning letter delivered from FDA to fill/finish manufacturer. On Friday after market close, Momenta announced that Pfizer, Sandoz's contracted manufacturer for Glatopa, had received an FDA warning letter. While the facility is a key portion of Momenta's supply chain for Glatopa 20mg, the warning letter is not expected to restrict production or shipments. Since the Pfizer facility is where the final Glatopa 40 mg product will be manufactured, FDA policy states that compliance observations must be satisfactorily resolved before the ANDA can move forward. We anticipate this will translate into a 6-month delay for Glatopa 40 mg." (2/21/2017)
  • 4. Maxim Group analysts commented, "The District Court of Delaware ruled to invalidate several of Teva’s (TEVA- $33.43-Hold) patents protecting 40mg (3x weekly) Copaxone; Patents ‘250, ‘413, ‘302, and ‘776. In 2016, the Patent Trial and Appeal Board (PTAB) declared these patents invalid due to obviousness through an inter partes review (IPR) proceeding." (2/1/2017)

Who are some of Momenta Pharmaceuticals' key competitors?

Who are Momenta Pharmaceuticals' key executives?

Momenta Pharmaceuticals' management team includes the folowing people:

  • Craig A. Wheeler, President, Chief Executive Officer, Director (Age 56)
  • Scott M. Storer, Chief Financial Officer, Senior Vice President (Age 42)
  • Ganesh Venkataraman Kaundinya Ph.D., Chief Operating Officer, Chief Scientific Officer (Age 51)
  • Bruce A. Leicher, Senior Vice President, General Counsel, Secretary (Age 60)
  • Bruce L. Downey, Independent Director (Age 69)
  • Corey N. Fishman, Independent Director (Age 52)
  • Georges Gemayel Ph.D., Independent Director (Age 56)
  • Steven C. Gilman Ph.D., Independent Director (Age 64)
  • Jose-Carlos Gutierrez-Ramos Ph.D., Independent Director (Age 54)

Who owns Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Schwab Charles Investment Management Inc. (0.54%), Acadian Asset Management LLC (0.39%) and Sicart Associates LLC (0.03%). Company insiders that own Momenta Pharmaceuticals stock include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner, Ganesh Venkataraman Kaundinya, James M Roach, John E Bishop and Richard P Shea. View Institutional Ownership Trends for Momenta Pharmaceuticals.

Who sold Momenta Pharmaceuticals stock? Who is selling Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC. Company insiders that have sold Momenta Pharmaceuticals company stock in the last year include Bruce Leicher, Craig A Wheeler, Elizabeth Stoner and Ganesh Venkataraman Kaundinya. View Insider Buying and Selling for Momenta Pharmaceuticals.

Who bought Momenta Pharmaceuticals stock? Who is buying Momenta Pharmaceuticals stock?

Momenta Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Sicart Associates LLC and Schwab Charles Investment Management Inc.. View Insider Buying and Selling for Momenta Pharmaceuticals.

How do I buy Momenta Pharmaceuticals stock?

Shares of Momenta Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Momenta Pharmaceuticals' stock price today?

One share of Momenta Pharmaceuticals stock can currently be purchased for approximately $16.40.

How big of a company is Momenta Pharmaceuticals?

Momenta Pharmaceuticals has a market capitalization of $1.23 billion and generates $109.62 million in revenue each year. The biotechnology company earns $-21,000,000.00 in net income (profit) each year or ($0.80) on an earnings per share basis. Momenta Pharmaceuticals employs 290 workers across the globe.

How can I contact Momenta Pharmaceuticals?

Momenta Pharmaceuticals' mailing address is 675 W Kendall St, CAMBRIDGE, MA 02142-1110, United States. The biotechnology company can be reached via phone at +1-617-4919700 or via email at [email protected]


MarketBeat Community Rating for Momenta Pharmaceuticals (MNTA)

Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  292 (Vote Outperform)
Underperform Votes:  252 (Vote Underperform)
Total Votes:  544
MarketBeat's community ratings are surveys of what our community members think about Momenta Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Momenta Pharmaceuticals (NASDAQ:MNTA) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 1.891.891.892.25
Ratings Breakdown: 1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
8 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
4 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $14.44$14.44$14.44$17.00
Price Target Upside: 2.44% upside2.44% upside4.67% upside9.32% upside

Momenta Pharmaceuticals (NASDAQ:MNTA) Consensus Price Target History

Price Target History for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ:MNTA) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/1/2017CowenSet Price TargetHold$15.00N/AView Rating Details
10/6/2017Robert W. BairdDowngradeBuy -> Hold$22.00 -> $15.00N/AView Rating Details
10/5/2017JPMorgan Chase & Co.Reiterated RatingHold$14.00N/AView Rating Details
10/5/2017Goldman Sachs GroupReiterated RatingNeutral$18.00 -> $14.00N/AView Rating Details
10/4/2017BarclaysReiterated RatingEqual Weight$17.00 -> $16.00HighView Rating Details
10/4/2017Stifel NicolausReiterated RatingBuy -> Hold$22.00 -> $15.00HighView Rating Details
8/3/2017Maxim GroupSet Price TargetSell$6.00LowView Rating Details
5/3/2017AegisReiterated RatingHold$17.00LowView Rating Details
2/21/2017Leerink SwannDowngradeOutperform -> Market Perform$18.00 -> $18.00N/AView Rating Details
8/5/2016Brean CapitalSet Price TargetBuy$19.00N/AView Rating Details
(Data available from 1/22/2016 forward)

Earnings

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings History and Estimates Chart

Earnings by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ MNTA) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/19/2018($0.18)N/AView Earnings Details
11/1/2017Q3 2017($0.47)($0.44)$29.58 million$24.09 millionViewN/AView Earnings Details
8/2/2017Q2 2017($0.50)($0.50)$24.64 million$23.57 millionViewListenView Earnings Details
5/2/2017Q1 2017($1.09)($0.46)$21.29 million$26.61 millionViewListenView Earnings Details
2/21/2017Q416($0.24)$0.60$29.56 million$34.20 millionViewListenView Earnings Details
11/2/2016Q316($0.29)($0.26)$25.68 million$299.14 millionViewN/AView Earnings Details
8/4/2016Q216($0.34)($0.31)$23.55 million$26.40 millionViewN/AView Earnings Details
5/3/2016Q116($0.32)($0.35)$28.12 million$19.90 millionViewN/AView Earnings Details
2/18/2016Q415($0.04)($0.43)$30.42 million$22.40 millionViewListenView Earnings Details
11/4/2015Q315($0.19)($0.44)$31.76 million$13.80 millionViewListenView Earnings Details
8/4/2015Q215($0.39)($0.04)$23.59 million$44.90 millionViewListenView Earnings Details
5/1/2015Q115($0.48)($0.40)$11.70 million$8.60 millionViewN/AView Earnings Details
2/17/2015Q414($0.16)($0.31)$23.80 million$21.18 millionViewListenView Earnings Details
11/5/2014Q314($0.43)($0.56)$13.00 million$9.34 millionViewListenView Earnings Details
7/31/2014Q214($0.49)($0.51)$11.22 million$11.00 millionViewListenView Earnings Details
5/6/2014Q1($0.55)($0.53)$8.41 million$10.79 millionViewListenView Earnings Details
2/10/2014Q4($0.45)($0.59)$8.50 million$12.80 millionViewListenView Earnings Details
11/5/2013Q313($0.48)($0.50)$8.60 million$10.80 millionViewN/AView Earnings Details
8/1/2013Q2 2013($0.45)($0.57)$8.85 million$4.40 millionViewN/AView Earnings Details
4/30/2013Q1 2013($0.44)($0.48)$10.28 million$7.60 millionViewN/AView Earnings Details
2/15/2013Q4 2012($0.41)($0.35)$10.41 million$12.70 millionViewN/AView Earnings Details
11/7/2012Q312($0.27)($0.51)$16.48 million$5.10 millionViewN/AView Earnings Details
8/2/2012($0.17)($0.20)ViewN/AView Earnings Details
5/3/2012$0.02($0.10)ViewN/AView Earnings Details
2/9/2012$0.13($0.02)ViewN/AView Earnings Details
11/7/2011$1.28$1.18ViewN/AView Earnings Details
8/4/2011$1.21$1.26ViewN/AView Earnings Details
5/5/2011$0.95$1.13ViewN/AView Earnings Details
2/10/2011$0.81$0.77ViewN/AView Earnings Details
11/1/2010Q3 2010$0.42$0.70ViewN/AView Earnings Details
8/2/2010Q2 2010($0.35)($0.34)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.34)($0.37)ViewN/AView Earnings Details
2/11/2010Q4 2009($0.35)($0.34)ViewN/AView Earnings Details
11/5/2009Q3 2009($0.40)($0.38)ViewN/AView Earnings Details
8/6/2009Q2 2009($0.44)($0.43)ViewN/AView Earnings Details
5/7/2009Q1 2009($0.47)($0.46)ViewN/AView Earnings Details
2/12/2009Q4 2008($0.44)($0.50)ViewN/AView Earnings Details
11/3/2008Q3 2008($0.43)($0.45)ViewN/AView Earnings Details
7/24/2008Q2 2008($0.43)($0.42)ViewN/AView Earnings Details
5/7/2008Q1 2008($0.56)($0.37)ViewN/AView Earnings Details
2/14/2008Q4 2007($0.60)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Momenta Pharmaceuticals (NASDAQ:MNTA) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.25 EPS

Dividends

Dividend History for Momenta Pharmaceuticals (NASDAQ:MNTA)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.40%
Institutional Ownership Percentage: 93.40%
Insider Trades by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)
Institutional Ownership by Quarter for Momenta Pharmaceuticals (NASDAQ:MNTA)

Momenta Pharmaceuticals (NASDAQ MNTA) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
1/2/2018Craig A WheelerCEOSell35,666$14.11$503,247.26View SEC Filing  
12/13/2017Elizabeth StonerDirectorSell5,500$13.10$72,050.0013,240View SEC Filing  
11/21/2017Bruce LeicherSVPSell803$13.15$10,559.45172,906View SEC Filing  
11/21/2017Craig A. WheelerCEOSell4,116$13.35$54,948.60View SEC Filing  
11/21/2017Ganesh Venkataraman KaundinyaCOOSell821$13.15$10,796.15487,633View SEC Filing  
11/10/2017Bruce LeicherSVPSell355$13.07$4,639.85173,322View SEC Filing  
11/10/2017Craig A WheelerCEOSell1,852$13.25$24,539.00258,602View SEC Filing  
11/10/2017Ganesh Venkataraman KaundinyaCOOSell392$13.12$5,143.04488,029View SEC Filing  
9/28/2017Craig A WheelerPresidentSell35,667$19.03$678,743.01286,121View SEC Filing  
9/1/2017Craig A. WheelerPresidentSell20,367$17.00$346,239.00View SEC Filing  
8/21/2017Bruce LeicherSVPSell802$15.20$12,190.40174,064View SEC Filing  
8/21/2017Craig A WheelerPresidentSell4,116$15.07$62,028.12269,231View SEC Filing  
8/21/2017Ganesh Venkataraman KaundinyaVPSell821$15.20$12,479.20488,846View SEC Filing  
8/10/2017Bruce LeicherSVPSell350$16.60$5,810.00View SEC Filing  
8/10/2017Craig A. WheelerPresidentSell16,953$16.94$287,183.82View SEC Filing  
8/10/2017Ganesh Venkataraman KaundinyaVPSell387$16.60$6,424.20489,242View SEC Filing  
8/2/2017Craig A WheelerPresidentSell200$17.00$3,400.00279,961View SEC Filing  
5/22/2017Bruce LeicherSVPSell859$14.80$12,713.20View SEC Filing  
5/19/2017Craig A WheelerPresidentSell4,116$15.83$65,156.28281,919View SEC Filing  
5/19/2017Ganesh Venkataraman KaundinyaVPSell821$15.90$13,053.90View SEC Filing  
5/10/2017Bruce LeicherSVPSell347$16.00$5,552.00175,205View SEC Filing  
5/10/2017Craig A. WheelerPresidentSell1,852$15.77$29,206.04View SEC Filing  
5/10/2017Ganesh Venkataraman KaundinyaVPSell384$16.00$6,144.00490,453View SEC Filing  
12/15/2016Richard P SheaCFOSell9,799$15.00$146,985.00121,972View SEC Filing  
12/9/2016Richard P SheaCFOSell1,451$15.00$21,765.00129,705View SEC Filing  
11/22/2016Bruce LeicherSVPSell1,030$13.66$14,069.80View SEC Filing  
11/22/2016Craig A. WheelerPresidentSell5,880$13.68$80,438.40View SEC Filing  
11/22/2016James M RoachVPSell1,091$13.67$14,913.97156,056View SEC Filing  
11/22/2016Richard P SheaCFOSell971$13.67$13,273.57131,731View SEC Filing  
8/22/2016Bruce LeicherSVPSell1,030$12.05$12,411.50183,566View SEC Filing  
8/22/2016Craig A. WheelerPresidentSell5,880$12.02$70,677.60View SEC Filing  
8/22/2016James M RoachVPSell1,091$12.05$13,146.55157,147View SEC Filing  
8/22/2016Richard P SheaCFOSell972$12.05$11,712.60132,703View SEC Filing  
5/20/2016Bruce LeicherSVPSell1,000$10.40$10,400.00184,576View SEC Filing  
5/20/2016Craig A WheelerPresidentSell5,880$10.18$59,858.40349,521View SEC Filing  
5/20/2016Ganesh Venkataraman KaundinyaVPSell1,050$10.18$10,689.00456,765View SEC Filing  
5/20/2016Richard P SheaCFOSell973$10.18$9,905.14133,675View SEC Filing  
5/19/2016John E BishopVPSell784$10.20$7,996.80157,640View SEC Filing  
4/19/2016John E BishopVPSell2,843$9.57$27,207.51160,880View SEC Filing  
2/23/2016John E BishopVPSell329$9.70$3,191.30107,188View SEC Filing  
2/22/2016Bruce LeicherSVPSell227$9.65$2,190.55131,188View SEC Filing  
2/22/2016Craig A WheelerPresidentSell1,688$9.95$16,795.60244,342View SEC Filing  
2/22/2016John E BishopVPSell2,848$9.66$27,511.68109,859View SEC Filing  
2/19/2016Bruce LeicherSVPSell2,000$9.64$19,280.00132,991View SEC Filing  
2/19/2016Craig A WheelerPresidentSell9,844$9.37$92,238.28253,905View SEC Filing  
2/19/2016John E. BishopVPSell357$10.28$3,669.96110,263View SEC Filing  
2/19/2016Richard P SheaCFOSell1,823$9.64$17,573.72141,924View SEC Filing  
2/18/2016Bruce LeicherSVPSell337$10.49$3,535.13133,415View SEC Filing  
2/18/2016James M RoachVPSell272$10.49$2,853.28107,269View SEC Filing  
2/18/2016Richard P SheaCFOSell183$10.49$1,919.67142,328View SEC Filing  
2/17/2016Craig A WheelerPresidentSell1,688$11.30$19,074.40255,874View SEC Filing  
12/11/2015Michael FrankenInsiderSell520$15.84$8,236.8037,968View SEC Filing  
11/20/2015Craig A WheelerPresidentSell1,766$17.86$31,540.76200,844View SEC Filing  
11/19/2015Craig A WheelerPresidentSell2,061$18.05$37,201.05202,610View SEC Filing  
11/17/2015Craig A WheelerPresidentSell1,766$17.70$31,258.20204,671View SEC Filing  
11/5/2015Craig A. WheelerPresidentSell51,667$18.00$930,006.00206,437View SEC Filing  
8/20/2015Craig A WheelerPresidentSell1,766$22.28$39,346.48212,719View SEC Filing  
8/19/2015Craig A WheelerPresidentSell2,061$22.02$45,383.22214,485View SEC Filing  
8/19/2015James M. RoachVPSell7,011$22.09$154,872.9992,079View SEC Filing  
8/18/2015James M RoachVPSell6,812$21.80$148,501.60View SEC Filing  
8/17/2015Craig A WheelerPresidentSell1,766$21.77$38,445.82216,546View SEC Filing  
7/15/2015Elizabeth StonerDirectorSell4,570$22.35$102,139.50View SEC Filing  
6/19/2015John E BishopVPSell21,274$25.50$542,487.00View SEC Filing  
6/18/2015Bruce LeicherSVPSell20,000$23.00$460,000.00View SEC Filing  
6/18/2015Craig A WheelerPresidentSell155,000$24.20$3,751,000.00View SEC Filing  
6/18/2015John E BishopVPSell36,313$23.58$856,260.54View SEC Filing  
6/4/2015Craig A WheelerPresidentSell103,333$22.00$2,273,326.00View SEC Filing  
6/1/2015Bruce LeicherSVPSell40,000$21.00$840,000.00View SEC Filing  
6/1/2015James M RoachVPSell25,000$21.70$542,500.00View SEC Filing  
5/20/2015Craig A WheelerPresidentSell1,766$19.68$34,754.88View SEC Filing  
5/19/2015Craig A WheelerPresidentSell2,061$19.67$40,539.87View SEC Filing  
4/23/2015Craig A WheelerPresidentSell51,667$20.00$1,033,340.00View SEC Filing  
4/23/2015Ganesh Venkataraman KaundinyaVPSell34,000$19.95$678,300.00View SEC Filing  
4/20/2015Craig A WheelerPresidentSell6,269$18.75$117,543.75View SEC Filing  
4/17/2015Bruce LeicherSVPSell52,910$19.52$1,032,803.20View SEC Filing  
4/16/2015James M RoachVPSell50,000$18.70$935,000.00View SEC Filing  
3/16/2015Richard P SheaCFOSell23,093$15.10$348,704.30View SEC Filing  
3/5/2015Richard P SheaCFOSell23,364$14.90$348,123.60View SEC Filing  
2/24/2015Craig A WheelerPresidentSell2,110$13.52$28,527.20View SEC Filing  
2/20/2015Bruce LeicherSVPSell1,891$12.97$24,526.27View SEC Filing  
2/20/2015Craig A WheelerPresidentSell9,563$13.49$129,004.87View SEC Filing  
2/20/2015John E BishopVPSell1,768$12.97$22,930.96View SEC Filing  
2/20/2015Richard P SheaCFOSell1,812$12.97$23,501.64View SEC Filing  
2/18/2015Craig A WheelerPresidentSell1,688$11.91$20,104.08View SEC Filing  
12/15/2014Bennett M ShapiroDirectorSell5,800$12.19$70,702.00View SEC Filing  
12/11/2014Michael FrankenInsiderSell2,047$12.29$25,157.63View SEC Filing  
12/1/2014Bennett M ShapiroDirectorSell9,903$12.00$118,836.00View SEC Filing  
11/28/2014Bennett M ShapiroDirectorSell1,897$12.00$22,764.00View SEC Filing  
11/25/2014Craig A WheelerPresidentSell2,210$11.59$25,613.90View SEC Filing  
11/20/2014Craig A WheelerPresidentSell1,768$11.10$19,624.80View SEC Filing  
11/17/2014Craig A WheelerPresidentSell1,768$10.58$18,705.44View SEC Filing  
10/3/2014Bennett M ShapiroDirectorSell3,723$12.00$44,676.00View SEC Filing  
9/12/2014Peter Barton HuttDirectorSell3,640$11.42$41,568.80View SEC Filing  
8/25/2014Craig A WheelerPresidentSell2,209$11.45$25,293.05View SEC Filing  
8/20/2014Craig A WheelerPresidentSell1,768$11.54$20,402.72View SEC Filing  
8/15/2014Bennett M ShapiroDirectorSell3,722$12.00$44,664.00View SEC Filing  
8/15/2014Craig A WheelerPresidentSell1,768$11.75$20,774.00View SEC Filing  
8/13/2014Bennett M ShapiroDirectorSell3,721$12.00$44,652.00View SEC Filing  
5/23/2014Craig A WheelerPresidentSell2,110$12.06$25,446.60View SEC Filing  
5/20/2014Craig WheelerPresidentSell1,688$12.08$20,391.04376,164View SEC Filing  
5/15/2014Craig WheelerPresidentSell1,687$11.09$18,708.83377,852View SEC Filing  
2/25/2014Craig WheelerPresidentSell2,109$17.47$36,844.23379,539View SEC Filing  
2/24/2014John BishopVPSell1,038$17.67$18,341.46111,621View SEC Filing  
2/19/2014Craig WheelerPresidentSell3,797$17.90$67,966.30388,398View SEC Filing  
2/12/2014Ganesh Venkataraman KaundinyaVPSell33,000$17.96$592,680.00346,129View SEC Filing  
1/9/2014John BishopVPSell27,159$19.50$529,600.5093,780View SEC Filing  
11/25/2013Bruce LeicherSVPSell13,492$18.00$242,856.00108,975View SEC Filing  
11/25/2013Craig WheelerPresidentSell2,215$17.77$39,360.55322,195View SEC Filing  
11/25/2013Ganesh Venkataraman KaundinyaVPSell33,211$18.02$598,462.22391,129View SEC Filing  
11/19/2013Craig WheelerPresidentSell2,215$17.17$38,031.55324,410View SEC Filing  
11/15/2013Craig WheelerPresidentSell1,772$16.88$29,911.36326,625View SEC Filing  
10/11/2013John BishopVPSell5,247$15.46$81,118.6294,618View SEC Filing  
8/23/2013Craig WheelerPresidentSell2,109$14.90$31,424.10328,397View SEC Filing  
8/20/2013Craig WheelerPresidentSell2,109$14.47$30,517.23330,506View SEC Filing  
8/15/2013Craig WheelerPresidentSell1,688$15.43$26,045.84332,615View SEC Filing  
7/26/2013Richard P SheaCFOSell30,000$16.61$498,300.00View SEC Filing  
6/27/2013Richard P SheaCFOSell10,522$14.61$153,726.42View SEC Filing  
6/19/2013Richard P SheaCFOSell21,550$14.61$314,845.50View SEC Filing  
5/23/2013Craig A WheelerPresidentSell2,109$13.03$27,480.27View SEC Filing  
5/21/2013Craig A WheelerPresidentSell2,109$12.83$27,058.47View SEC Filing  
5/15/2013Craig A WheelerPresidentSell1,687$13.33$22,487.71View SEC Filing  
3/5/2013Elizabeth StonerDirectorSell2,040$14.00$28,560.00View SEC Filing  
2/15/2013Bruce LeicherSVPSell1,040$12.26$12,750.40View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Momenta Pharmaceuticals (NASDAQ MNTA) News Headlines

Source:
DateHeadline
Momenta Pharmaceuticals, Inc. Continues Its Rollercoaster RideMomenta Pharmaceuticals, Inc. Continues Its Rollercoaster Ride
www.fool.com - January 12 at 10:49 PM
Here's Why Momenta Pharmaceuticals, Inc. Reversed Course TodayHere's Why Momenta Pharmaceuticals, Inc. Reversed Course Today
finance.yahoo.com - January 8 at 5:42 PM
Heres Why Momenta Pharmaceuticals, Inc. Reversed Course Today Here's Why Momenta Pharmaceuticals, Inc. Reversed Course Today
www.fool.com - January 8 at 2:37 PM
Momenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of "Hold" from BrokeragesMomenta Pharmaceuticals, Inc. (MNTA) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - January 8 at 9:58 AM
Momenta Phama (MNTA) Announces Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281Momenta Phama (MNTA) Announces Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281
www.streetinsider.com - January 6 at 5:26 PM
MNTA Makes Bullish Cross Above Critical Moving AverageMNTA Makes Bullish Cross Above Critical Moving Average
www.nasdaq.com - January 5 at 5:17 PM
Why Momenta Pharmaceuticals Rallied 15.6% TodayWhy Momenta Pharmaceuticals Rallied 15.6% Today
www.fool.com - January 5 at 3:12 PM
Momenta Pharmaceuticals (MNTA) and Idera Pharmaceuticals (IDRA) Head to Head ReviewMomenta Pharmaceuticals (MNTA) and Idera Pharmaceuticals (IDRA) Head to Head Review
www.americanbankingnews.com - January 5 at 1:42 PM
Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281,Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281,
www.nasdaq.com - January 5 at 9:22 AM
Momenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy VolunteersMomenta Pharmaceuticals Reports Positive Top-Line Phase 1 Data Showing Proof of Mechanism for M281, an Anti-FcRn Monoclonal Antibody, in Healthy Volunteers
finance.yahoo.com - January 5 at 9:22 AM
Momenta & Mylan to Initiate Trial on Biosimilar of EyleaMomenta & Mylan to Initiate Trial on Biosimilar of Eylea
finance.yahoo.com - January 4 at 9:15 AM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 35,666 SharesMomenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 35,666 Shares
www.americanbankingnews.com - January 3 at 7:02 PM
Zacks Investment Research Upgrades Momenta Pharmaceuticals (MNTA) to "Hold"Zacks Investment Research Upgrades Momenta Pharmaceuticals (MNTA) to "Hold"
www.americanbankingnews.com - January 2 at 12:00 PM
Momenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare ConferenceMomenta Pharmaceuticals to Webcast Presentation at the 36th Annual J. P. Morgan Healthcare Conference
finance.yahoo.com - December 28 at 8:18 AM
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : December 26, 2017Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : MNTA-US : December 26, 2017
finance.yahoo.com - December 26 at 2:23 PM
Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : December 18, 2017Momenta Pharmaceuticals, Inc. – Value Analysis (NASDAQ:MNTA) : December 18, 2017
finance.yahoo.com - December 19 at 9:15 AM
Momenta Pharmaceuticals, Inc. (MNTA) Director Elizabeth Stoner Sells 5,500 SharesMomenta Pharmaceuticals, Inc. (MNTA) Director Elizabeth Stoner Sells 5,500 Shares
www.americanbankingnews.com - December 15 at 2:40 PM
Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : December 15, 2017Momenta Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : MNTA-US : December 15, 2017
finance.yahoo.com - December 15 at 9:34 AM
Momenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of "Hold" by AnalystsMomenta Pharmaceuticals, Inc. (MNTA) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - December 14 at 10:10 AM
Stock Traders Buy Large Volume of Put Options on Momenta Pharmaceuticals (MNTA)Stock Traders Buy Large Volume of Put Options on Momenta Pharmaceuticals (MNTA)
www.americanbankingnews.com - December 14 at 4:10 AM
BidaskClub Downgrades Momenta Pharmaceuticals (MNTA) to HoldBidaskClub Downgrades Momenta Pharmaceuticals (MNTA) to Hold
www.americanbankingnews.com - December 9 at 1:38 PM
Momenta Pharmaceuticals (MNTA) Lowered to Sell at Zacks Investment ResearchMomenta Pharmaceuticals (MNTA) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - December 4 at 9:52 AM
ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 28, 2017ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 28, 2017
finance.yahoo.com - November 28 at 5:31 PM
Momenta Pharmaceuticals, Inc. (MNTA) SVP Sells $10,559.45 in StockMomenta Pharmaceuticals, Inc. (MNTA) SVP Sells $10,559.45 in Stock
www.americanbankingnews.com - November 22 at 10:36 AM
Ganesh Venkataraman Kaundinya Sells 821 Shares of Momenta Pharmaceuticals, Inc. (MNTA) StockGanesh Venkataraman Kaundinya Sells 821 Shares of Momenta Pharmaceuticals, Inc. (MNTA) Stock
www.americanbankingnews.com - November 22 at 10:34 AM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 4,116 SharesMomenta Pharmaceuticals, Inc. (MNTA) CEO Craig A. Wheeler Sells 4,116 Shares
www.americanbankingnews.com - November 22 at 10:32 AM
Momenta Pharmaceuticals, Inc. (MNTA) Given Consensus Rating of "Hold" by BrokeragesMomenta Pharmaceuticals, Inc. (MNTA) Given Consensus Rating of "Hold" by Brokerages
www.americanbankingnews.com - November 19 at 9:50 AM
ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 15, 2017ETFs with exposure to Momenta Pharmaceuticals, Inc. : November 15, 2017
finance.yahoo.com - November 17 at 10:48 PM
Momenta Pharmaceuticals (MNTA) and Its Rivals Head to Head ContrastMomenta Pharmaceuticals (MNTA) and Its Rivals Head to Head Contrast
www.americanbankingnews.com - November 16 at 10:24 AM
Comparing Momenta Pharmaceuticals (MNTA) and Its RivalsComparing Momenta Pharmaceuticals (MNTA) and Its Rivals
www.americanbankingnews.com - November 16 at 1:06 AM
Momenta Pharmaceuticals, Inc. (MNTA) CEO Sells $24,539.00 in StockMomenta Pharmaceuticals, Inc. (MNTA) CEO Sells $24,539.00 in Stock
www.americanbankingnews.com - November 14 at 5:06 PM
Momenta Pharmaceuticals Stock Sees Short Interest Move 10.3% HigherMomenta Pharmaceuticals Stock Sees Short Interest Move 10.3% Higher
www.thestreet.com - November 12 at 7:45 AM
Momenta Pharmaceuticals, Inc.'s Rough MonthMomenta Pharmaceuticals, Inc.'s Rough Month
finance.yahoo.com - November 12 at 7:45 AM
Momenta Pharmaceuticals, Inc.s Rough MonthMomenta Pharmaceuticals, Inc.'s Rough Month
www.fool.com - November 10 at 3:57 PM
Momenta Pharmaceuticals (MNTA) and Its Peers Head-To-Head AnalysisMomenta Pharmaceuticals (MNTA) and Its Peers Head-To-Head Analysis
www.americanbankingnews.com - November 8 at 3:58 PM
Momenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare ConferenceMomenta Pharmaceuticals to Webcast Presentation at the Stifel 2017 Healthcare Conference
finance.yahoo.com - November 8 at 3:49 PM
Generic Drugs Stock Performance Review - Medicines Co., Momenta Pharma, Diplomat Pharmacy, and ZoetisGeneric Drugs Stock Performance Review - Medicines Co., Momenta Pharma, Diplomat Pharmacy, and Zoetis
www.prnewswire.com - November 7 at 6:56 AM
Momentas (MNTA) Biosimilar Study Fails, Q3 Loss NarrowsMomenta's (MNTA) Biosimilar Study Fails, Q3 Loss Narrows
finance.yahoo.com - November 4 at 5:26 AM
Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017Momenta Pharmaceuticals, Inc. :MNTA-US: Earnings Analysis: Q3, 2017 By the Numbers : November 3, 2017
finance.yahoo.com - November 4 at 5:26 AM
Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)Momenta and Mylan Report Initial Results from Phase 1 Clinical Trial for M834, a Proposed Biosimilar of ORENCIA® (abatacept)
finance.yahoo.com - November 2 at 6:29 AM
Momenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate UpdateMomenta Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - November 2 at 6:29 AM
Momenta reports 3Q lossMomenta reports 3Q loss
finance.yahoo.com - November 2 at 6:29 AM
Momenta shares plunge 14% on Q3 profit, revenue missesMomenta shares plunge 14% on Q3 profit, revenue misses
finance.yahoo.com - November 2 at 6:29 AM
Momenta Shares Down On Phase 1 Data for Biosimilar -- Biotech MoversMomenta Shares Down On Phase 1 Data for Biosimilar -- Biotech Movers
finance.yahoo.com - November 2 at 6:29 AM
Edited Transcript of MNTA earnings conference call or presentation 1-Nov-17 2:00pm GMTEdited Transcript of MNTA earnings conference call or presentation 1-Nov-17 2:00pm GMT
finance.yahoo.com - November 2 at 6:29 AM
Why Momenta Pharmaceuticals Fell 12.6% TodayWhy Momenta Pharmaceuticals Fell 12.6% Today
www.fool.com - November 1 at 4:41 PM
Momenta Pharmaceuticals, Inc. (MNTA) Announces  Earnings Results, Beats Expectations By $0.03 EPSMomenta Pharmaceuticals, Inc. (MNTA) Announces Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - November 1 at 3:14 PM
ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 6:28 AM
ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017ETFs with exposure to Momenta Pharmaceuticals, Inc. : October 30, 2017
finance.yahoo.com - October 31 at 6:28 AM
Momenta Pharmaceuticals, Inc. (MNTA) Short Interest UpdateMomenta Pharmaceuticals, Inc. (MNTA) Short Interest Update
www.americanbankingnews.com - October 26 at 1:40 AM

SEC Filings

Momenta Pharmaceuticals (NASDAQ:MNTA) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Momenta Pharmaceuticals (NASDAQ:MNTA) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Momenta Pharmaceuticals (NASDAQ MNTA) Stock Chart for Monday, January, 22, 2018

Loading chart…

This page was last updated on 1/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.